Home / Health / GLP-1 Drugs: Real-World Data Challenges Weight Regain Fears
GLP-1 Drugs: Real-World Data Challenges Weight Regain Fears
22 Jan
Summary
- Most patients maintained weight loss 18 months after stopping GLP-1 drugs.
- Exercise counseling doubled likelihood of sustained weight loss post-treatment.
- New analysis suggests weight regain may be less common than previously thought.
An analysis of real-world data indicates that many patients using GLP-1 drugs, such as Wegovy and Ozempic, may not quickly regain lost weight after discontinuing treatment. Researchers from nference analyzed data from a large U.S. academic medical clinic network.
Contrary to some findings from clinical trials, this observational study suggests that a significant portion of patients maintained their weight loss or continued to lose more weight 18 months after stopping semaglutide or tirzepatide. This durability of effect offers hope for managing obesity as a chronic condition.
Patients who received exercise counseling post-treatment were almost twice as likely to maintain weight loss compared to those who did not. Researchers also noted that while study limitations exist, the findings suggest weight regain might be less prevalent than widely reported.
AI was used to analyze millions of doctors' notes and clinical data entries. Among tirzepatide users who stopped, about 36% maintained weight loss and 36% continued to lose weight six months later. For semaglutide users who discontinued, 32% maintained their loss and 35% continued to lose weight.
